Literature DB >> 12860177

Lipopeptide adjuvants in combination treatment.

Wolfgang G Bessler1, K Mittenbühler, U v d Esche, M Huber.   

Abstract

Synthetic lipopeptides derived from the N-terminus of bacterial lipoprotein constitute potent immunoadjuvants for parenteral and mucosal immunization. When combined with tetanus toxoid (TT) or gliadin as antigens, the lipopeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-seryl-(lysyl)(3)-lysine (P(3)CSK(4)) markedly enhanced the specific antibody levels. Lipopeptides also act as macrophage/monocyte activators: P(3)CSK(4) induced nitric oxide release from bone marrow-derived macrophages (BMDM) of LPS responder and nonresponder mice. The antitumoral effect of the lipopeptide was demonstrated by a strong cytostatic activity of the lipopeptide-treated macrophages against the murine B-cell lymphoma cell line Abelson 8-1. The chemically well-defined lipopeptides can be synthesized with high purity and reproducibility and constitute ideal agents to be combined with antigens/vaccines or antitumor treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860177     DOI: 10.1016/s1567-5769(03)00027-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  Lipopeptides rather than lipopolysaccharide favor the development of dendritic cell dysfunction similar to polymicrobial sepsis in mice.

Authors:  Stephanie Bruns; Eva Pastille; Florian Wirsdörfer; Marion Frisch; Stefanie B Flohé
Journal:  Inflamm Res       Date:  2013-04-03       Impact factor: 4.575

2.  Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists.

Authors:  Richard Kenmoe Kamgang; Inês Ramos; Lurdes Rodrigues Duarte; Mascia Ghielmetti; Marina Freudenberg; Clemens Dahinden; Elisabetta Padovan
Journal:  Med Microbiol Immunol       Date:  2008-02-19       Impact factor: 3.402

3.  A purified recombinant lipopeptide as adjuvant for cancer immunotherapy.

Authors:  Ying-Chyi Song; Hsueh-Hung Liu; I-Hua Chen; Hsin-Wei Chen; Pele Chong; Chih-Hsiang Leng; Shih-Jen Liu
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

Review 4.  Innate Immune Responses in Leprosy.

Authors:  Roberta Olmo Pinheiro; Veronica Schmitz; Bruno Jorge de Andrade Silva; André Alves Dias; Beatriz Junqueira de Souza; Mayara Garcia de Mattos Barbosa; Danuza de Almeida Esquenazi; Maria Cristina Vidal Pessolani; Euzenir Nunes Sarno
Journal:  Front Immunol       Date:  2018-03-28       Impact factor: 7.561

5.  Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model.

Authors:  Okechukwu C Ndumnego; Susanne M Koehler; Jannie E Crafford; Wolfgang Beyer; Henriette van Heerden
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.